Aadi Bioscience Inc
NASDAQ:AADI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aadi Bioscience Inc
NASDAQ:AADI
|
US |
|
Christie Group plc
LSE:CTG
|
UK |
|
R
|
Rational AG
SWB:RAA
|
DE |
|
Lagnam Spintex Ltd
NSE:LAGNAM
|
IN |
|
G
|
Geely Automobile Holdings Ltd
XBER:GRU
|
HK |
|
Gusbourne PLC
LSE:GUS
|
UK |
|
C
|
Cyient DLM Ltd
NSE:CYIENTDLM
|
IN |
|
H
|
Hub.Tech SA
WSE:HUB
|
PL |
|
A
|
Alibaba Group Holding Ltd
HKEX:9988
|
CN |
|
Wihlborgs Fastigheter AB
STO:WIHL
|
SE |
|
Marsden Maritime Holdings Ltd
NZX:MMH
|
NZ |
|
S
|
Samtex Fashions Ltd
BSE:521206
|
IN |
|
Clime Investment Management Ltd
ASX:CIW
|
AU |
|
P
|
Paikkwang Industrial Co Ltd
KRX:001340
|
KR |
|
Mayne Pharma Group Ltd
ASX:MYX
|
AU |
|
ABC-Mart Inc
OTC:AMKYF
|
JP |
|
E
|
Expleo Solutions Ltd
NSE:EXPLEOSOL
|
IN |
|
E
|
Eli Lilly and Co
XETRA:LLY
|
US |
|
C
|
China Hongkong Photo Products Holdings Ltd
HKEX:1123
|
HK |
|
Fantasia Holdings Group Co Ltd
HKEX:1777
|
CN |
|
Fermenta Biotech Ltd
BSE:506414
|
IN |
|
A
|
Aeris Industria e Comercio de Equipamentos para Geracao de Energia SA
BOVESPA:AERI3
|
BR |
|
J
|
John Menzies PLC
F:B3N
|
UK |
|
Metropolitan Bank and Trust Co
XPHS:MBT
|
PH |
Aadi Bioscience Inc
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 39 full-time employees. The company went IPO on 2018-06-26. The Company’s primary focus is to bring transformational therapies to cancer patients with mechanistic target of rapamycin (mTOR) pathway driver alterations such as alterations in TSC1 or TSC2 genes. The Company’s initial focus is the treatment of an ultra-rare cancer perivascular epithelioid cell tumor (PEComa). The Company’s lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models. FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa).
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 39 full-time employees. The company went IPO on 2018-06-26. The Company’s primary focus is to bring transformational therapies to cancer patients with mechanistic target of rapamycin (mTOR) pathway driver alterations such as alterations in TSC1 or TSC2 genes. The Company’s initial focus is the treatment of an ultra-rare cancer perivascular epithelioid cell tumor (PEComa). The Company’s lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models. FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
